1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming

 
• By Alaric DeArment

The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.

Array of blood samples for microscopy and biopsy tissue on blue gradient background

A subcutaneous formulation of argenx N.V.’s Vyvgart (efgartigimod alfa-fcab) – currently available as an intravenous drug – would no doubt benefit patients from a convenience standpoint. However, the intravenous formulation may continue to have significant utility as the company works to expand its labeling into primary immune thrombocytopenia (ITP), a type of rare platelet disorder.

The company presented updated data from its pivotal Phase III ADVANCE study of Vyvgart in ITP during an 11 December...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

More from R&D

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.